

The proposed change may be discussed at meetings of the Advisory Board on Radiation and Worker Health on January 9, 2006 (teleconference) and January 24–26, 2006 in Oak Ridge, TN. Only after the close of the public comment period will NIOSH make a final decision regarding the proposed change.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: January 10, 2006.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E6–542 Filed 1–18–06; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Portfolio Review of Single Gene Disorders and Disability

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

*Name:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Portfolio Review of Single Gene Disorders and Disability.

*Times and Dates:* 9 a.m.–5 p.m., February 10, 2006 (Closed).

*Place:* National Center on Birth Defects and Developmental Disabilities, CDC, 12 Executive Park Drive, Atlanta, GA 30329, Telephone Number 404.498.3800.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

*Matters to be Discussed:* The meeting will include the review and discussion of the Single Gene Disorders and Disability Team's strategies and activities.

*For Further Information Contact:* Esther Sumartojo, Acting Associate Director for Science and Public Health, National Center on Birth Defects and Developmental Disabilities, CDC, 1600 Clifton Road, NE., Mailstop E–87, Atlanta, GA 30333, Telephone Number 404.498.3800.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: January 12, 2006.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E6–538 Filed 1–18–06; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following federal advisory committee meeting:

*Name:* National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect (NTFFASFAE).

*Times and Dates:* 8:30 a.m.–4:30 p.m., February 16, 2006. 8:30 a.m.–1 p.m., February 17, 2006.

*Place:* Embassy Suites Hotel Buckhead, 3285 Peachtree Road, NE., Atlanta, Georgia 30305, telephone 404/261–7733, fax 404/262–0522.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 65 people.

*Purpose:* The Secretary is authorized by the Public Health Service Act, section 399G (42 U.S.C. Section 280f, as added by Pub. L. 105–392), to establish a NTFFASFAE to: (1) Foster coordination among all governmental agencies, academic bodies and community groups that conduct or support Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Effect (FAE) research, programs and surveillance; and (2) to otherwise meet the general needs of populations actually or potentially impacted by FAS and FAE.

*Matters to be Discussed:* Agenda items include: (1) Discussion of the Task Force's Post-Exposure working group activities; (2) presentations regarding prevention initiatives from other relevant health topics such as tobacco use and HIV; (3) presentation and discussion regarding evidence-based review of FAS prevention strategies; (4) Task Force next steps; (5) updates from the Interagency Coordinating Committee on FAS, CDC, and other federal agencies, and liaison members; (6) and scheduling of the next meeting.

Agenda items are subject to change as priorities dictate.

*For Further Information Contact:* Mary Kate Weber, M.P.H., Executive Secretary, National Center on Birth Defects and

Developmental Disabilities, CDC, 1600 Clifton Road, NE., (E–86), Atlanta, Georgia 30333, telephone 404/498–3926, fax 404/498–3550.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and Agency for Toxic Substances and Disease Registry.

Dated: January 10, 2006.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. E6–543 Filed 1–18–06; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Committee on Immunization Practices: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following Federal committee meeting.

*Name:* Advisory Committee on Immunization Practices (ACIP).

*Time and Date:* 8 a.m.–6:15 p.m., February 21, 2006.

8 a.m.–5 p.m., February 22, 2006.

*Place:* Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Building 19, Room 232, Atlanta, Georgia 30333.

*Status:* Open to the public, limited only by the space available.

*Purpose:* The committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

*Matters To Be Discussed:* The agenda will include discussions on Rotavirus Vaccine which may include a possible VFC Vote; Human Papillomavirus Vaccine; general recommendations on immunization; Influenza; Herpes Zoster Vaccine; Tetanus Toxoid, Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccines; and departmental updates.

Agenda items are subject to change as priorities dictate.

*For Further Information Contact:* Demetria Gardner, Epidemiology and Surveillance Division, National Immunization Program, CDC, 1600 Clifton Road, NE., (E–61), Atlanta, Georgia 30333, telephone 404/639–8096, fax 404/639–8616.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

Dated: January 10, 2006.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E6-529 Filed 1-18-06; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2006N-0010]

#### **Able Laboratories, Inc.; Withdrawal of Approval of 43 Abbreviated New Drug Applications**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of 43 abbreviated new drug applications (ANDAs) held by Able Laboratories, Inc. (Able Labs), One Able Dr., Cranbury, NJ 08512. The drug

products are no longer marketed, and Able Labs has requested that the approval of the applications be withdrawn.

**DATES:** Effective January 19, 2006.

**FOR FURTHER INFORMATION CONTACT:** Florine P. Purdie, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

**SUPPLEMENTARY INFORMATION:** The applications listed in the table in this document are no longer marketed, and Able Labs has requested that FDA withdraw approval of the applications. The company has also, by its request, waived its opportunity for a hearing.

Application No.	Drug
40-390	Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 milligrams (mg)/325 mg/40 mg
40-394	Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/500 mg/40 mg
40-402	Phentermine Hydrochloride (HCl) Tablets USP, 37.5 mg
40-403	Phentermine HCl Capsules USP, 30 mg (powder)
40-413	Methocarbamol Tablets USP, 500 mg and 750 mg
40-421	Carisoprodol Tablets USP, 350 mg
40-427	Phentermine HCl Capsules USP, 30 mg (beads)
40-449	Promethazine HCl Suppositories USP, 50 mg
40-464	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/325 mg and 10 mg/325 mg
40-469	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/750 mg
40-473	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 10 mg/500 mg
40-474	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/650 mg
40-476	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 10 mg/650 mg
40-477	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/500 mg
40-478	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/325 mg
40-483	Bethanechol Chloride Tablets USP, 10 mg
40-485	Bethanechol Chloride Tablets USP, 25 mg
40-490	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/500 mg
40-492	Bethanechol Chloride Tablets USP, 5 mg
40-497	Phentermine HCl Capsules USP, 15 mg
40-504	Promethazine HCl Suppositories USP, 12.5 mg and 25 mg
40-509	Bethanechol Chloride Tablets USP, 50 mg
40-529	Methamphetamine HCl Tablets USP, 5 mg
40-539	Theophylline Extended-Release Tablets, 600 mg
40-543	Theophylline Extended-Release Tablets, 400 mg
40-546	Theophylline Extended-Release Tablets, 450 mg